Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | EEF2K | O00418 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035971 | 0.85 | SMN1; SMN2 (0.63) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| SCHEMBL6771405 | 0.85 | HRH3 (0.68) | ALDH1A1SMN1; SMN2LMNAPKMNPSR1 | |
| SCHEMBL5247018 | 0.82 | FAAH (0.63) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| SCHEMBL8192193 | 0.80 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| Hydrochloric Acid SCHEMBL27884130 | 0.80 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2LMNAPKMNPSR1 | |
| SCHEMBL8188406 | 0.80 | ALDH1A1 (0.86) | ALDH1A1SMN1; SMN2LMNAKDM4EKMT2A | |
| SCHEMBL15224104 | 0.80 | FAAH (0.60) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| SCHEMBL2841801 | 0.79 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| SCHEMBL544161 | 0.79 | SIGMAR1 (0.68) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH | |
| SCHEMBL1943497 | 0.79 | HRH3 (0.75) | ALDH1A1SMN1; SMN2LMNAKDM4EFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | ALDH1A1 2039/4885SMN1; SMN2 331/4885LMNA 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.